Pak Fah Yeow International Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Pak Fah Yeow International has been growing earnings at an average annual rate of 42.9%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 14.9% per year. Pak Fah Yeow International's return on equity is 12.8%, and it has net margins of 36.3%.
Belangrijke informatie
42.9%
Groei van de winst
42.9%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 5.6% |
Inkomstengroei | 14.9% |
Rendement op eigen vermogen | 12.8% |
Nettomarge | 36.3% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Why Pak Fah Yeow International's (HKG:239) Earnings Are Better Than They Seem
Sep 19Pak Fah Yeow International (HKG:239) Is Paying Out A Dividend Of HK$0.095
Aug 30Here's Why We Think Pak Fah Yeow International (HKG:239) Might Deserve Your Attention Today
Nov 21Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)
Aug 31Calculating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)
Jun 01Does Pak Fah Yeow International (HKG:239) Have A Healthy Balance Sheet?
Dec 12Pak Fah Yeow International's (HKG:239) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02The Strong Earnings Posted By Pak Fah Yeow International (HKG:239) Are A Good Indication Of The Strength Of The Business
Sep 24Pak Fah Yeow International (HKG:239) Will Pay A Larger Dividend Than Last Year At HK$0.028
Aug 28Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)
May 11Consider This Before Buying Pak Fah Yeow International Limited (HKG:239) For The 2.9% Dividend
Feb 21What Type Of Returns Would Pak Fah Yeow International's(HKG:239) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 17How Does Pak Fah Yeow International Limited (HKG:239) Fare As A Dividend Stock?
Nov 21Opbrengsten en kosten
Hoe Pak Fah Yeow International geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 266 | 96 | 57 | 0 |
31 Mar 24 | 263 | 101 | 56 | 0 |
31 Dec 23 | 260 | 105 | 55 | 0 |
30 Sep 23 | 238 | 97 | 52 | 0 |
30 Jun 23 | 217 | 88 | 49 | 0 |
31 Mar 23 | 183 | 59 | 49 | 0 |
31 Dec 22 | 148 | 30 | 48 | 0 |
30 Sep 22 | 144 | 28 | 47 | 0 |
30 Jun 22 | 141 | 26 | 47 | 0 |
31 Mar 22 | 141 | 32 | 47 | 0 |
31 Dec 21 | 141 | 38 | 47 | 0 |
30 Sep 21 | 131 | 29 | 43 | 0 |
30 Jun 21 | 121 | 19 | 40 | 0 |
31 Mar 21 | 115 | -10 | 39 | 0 |
31 Dec 20 | 110 | -38 | 39 | 0 |
30 Sep 20 | 114 | -35 | 46 | 0 |
30 Jun 20 | 119 | -32 | 53 | 0 |
31 Mar 20 | 134 | 2 | 53 | 0 |
31 Dec 19 | 148 | 36 | 53 | 0 |
30 Sep 19 | 160 | 40 | 54 | 0 |
30 Jun 19 | 171 | 45 | 54 | 0 |
31 Mar 19 | 156 | 41 | 54 | 0 |
31 Dec 18 | 142 | 37 | 54 | 0 |
30 Sep 18 | 144 | 52 | 43 | 0 |
30 Jun 18 | 147 | 66 | 32 | 0 |
31 Mar 18 | 163 | 84 | 33 | 0 |
31 Dec 17 | 180 | 103 | 34 | 0 |
30 Sep 17 | 183 | 104 | 33 | 0 |
30 Jun 17 | 186 | 106 | 32 | 0 |
31 Mar 17 | 185 | 84 | 31 | 0 |
31 Dec 16 | 183 | 61 | 31 | 0 |
30 Sep 16 | 176 | 48 | 31 | 0 |
30 Jun 16 | 170 | 34 | 32 | 0 |
31 Mar 16 | 176 | 48 | 32 | 0 |
31 Dec 15 | 183 | 61 | 32 | 0 |
30 Sep 15 | 189 | 91 | 34 | 0 |
30 Jun 15 | 195 | 122 | 35 | 0 |
31 Mar 15 | 191 | 134 | 34 | 0 |
31 Dec 14 | 187 | 146 | 33 | 0 |
30 Sep 14 | 176 | 121 | 31 | 0 |
30 Jun 14 | 164 | 96 | 30 | 0 |
31 Mar 14 | 163 | 83 | 29 | 0 |
31 Dec 13 | 162 | 71 | 28 | 0 |
Kwaliteitswinsten: 239 has high quality earnings.
Groeiende winstmarge: 239's current net profit margins (36.3%) are lower than last year (40.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 239's earnings have grown significantly by 42.9% per year over the past 5 years.
Versnelling van de groei: 239's earnings growth over the past year (9.4%) is below its 5-year average (42.9% per year).
Winst versus industrie: 239 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry 6.4%.
Rendement op eigen vermogen
Hoge ROE: 239's Return on Equity (12.8%) is considered low.